This would be consistent with the notion that methylation of JMJD2D could promote prostate cancer development through upregulation of CBLC and METTL27 as well as through downregulation of COL4A5, GLIS3, NPR1, OSR2, PLAGL1 and RSPO3. The gene discussed is GLIS3; the disease is prostate carcinoma.